REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

Petra Seibold; Adam Webb; Miguel E. Aguado-Barrera; David Azria; Celine Bourgier; Muriel Brengues; Erik Briers; Renee Bultijnck; Patricia Calvo-Crespo; Ana Carballo; Ananya Choudhury; Alessandro Cicchetti; Johannes Classen; Elena Delmastro; Alison M. Dunning; Rebecca M. Elliott; Laura Fachal; Marie-Pierre Farcy-Jacquet; Pietro Gabriele; Elisabetta Garibaldi; Antonio Gomez-Caamano; Sara Gutierrez-Enriquez; Daniel S. Higginson; Kerstie Johnson; Ramon Lobato-Busto; Meritxell Molla; Anusha Mueller; Debbie Payne; Paula Peleteiro; Giselle Post; Tiziana Rancati; Tim Rattay; Victoria Reyes; Barry S. Rosenstein; Dirk De Ruysscher; Maria Carmen De Santis; Joerg Schaefer; Thomas Schnabel; Elena Sperk; R. Paul Symonds; Hilary Stobart; Begona Taboada-Valladares; Christopher J. Talbot; Riccardo Valdagni; Ana Vega; Liv Veldeman; Tim Ward; Christian Weissenberger; Ben Vanneste; Ahmed Osman; REQUITE consortium

doi:10.1016/j.radonc.2019.04.034

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

Petra Seibold^*, Adam Webb, Miguel E. Aguado-Barrera, David Azria, Celine Bourgier, Muriel Brengues, Erik Briers, Renee Bultijnck, Patricia Calvo-Crespo, Ana Carballo, Ananya Choudhury, Alessandro Cicchetti, Johannes Classen, Elena Delmastro, Alison M. Dunning, Rebecca M. Elliott, Laura Fachal, Marie-Pierre Farcy-Jacquet, Pietro Gabriele, Elisabetta GaribaldiAntonio Gomez-Caamano, Sara Gutierrez-Enriquez, Daniel S. Higginson, Kerstie Johnson, Ramon Lobato-Busto, Meritxell Molla, Anusha Mueller, Debbie Payne, Paula Peleteiro, Giselle Post, Tiziana Rancati, Tim Rattay, Victoria Reyes, Barry S. Rosenstein, Dirk De Ruysscher, Maria Carmen De Santis, Joerg Schaefer, Thomas Schnabel, Elena Sperk, R. Paul Symonds, Hilary Stobart, Begona Taboada-Valladares, Christopher J. Talbot, Riccardo Valdagni, Ana Vega, Liv Veldeman, Tim Ward, Christian Weissenberger, Ben Vanneste, Ahmed Osman, REQUITE consortium

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Purpose: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data.

Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated.

Results: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician-(47,025 forms) and patient-(54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade >= 2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung).

Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers.

Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short-and long-term quality-of-life. Not all patients are equally sensitive to radiation "damage" but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available.

In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries.

In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity. (C) 2019 The Authors. Published by Elsevier B.V.

Original language	English
Pages (from-to)	59-67
Number of pages	9
Journal	Radiotherapy and Oncology
Volume	138
DOIs	https://doi.org/10.1016/j.radonc.2019.04.034
Publication status	Published - Sept 2019

Keywords

Late radiotherapy side effects
Biomarkers
Prediction models
Breast cancer
Prostate cancer
Lung cancer
QUALITY-OF-LIFE
GENOME-WIDE ASSOCIATION
DATA METAANALYSIS SHOWS
REPORTED OUTCOMES
RADIATION-THERAPY
EUROPEAN-ORGANIZATION
NO ASSOCIATION
LATE TOXICITY
RISK
POLYMORPHISMS

Access to Document

10.1016/j.radonc.2019.04.034Licence: CC BY-NC-ND

Cite this

Seibold, P., Webb, A., Aguado-Barrera, M. E., Azria, D., Bourgier, C., Brengues, M., Briers, E., Bultijnck, R., Calvo-Crespo, P., Carballo, A., Choudhury, A., Cicchetti, A., Classen, J., Delmastro, E., Dunning, A. M., Elliott, R. M., Fachal, L., Farcy-Jacquet, M.-P., Gabriele, P., ... REQUITE consortium (2019). REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology, 138, 59-67. https://doi.org/10.1016/j.radonc.2019.04.034

@article{c13730278ab540448cbb9c260e738bf8,

title = "REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer",

abstract = "Purpose: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data.Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated.Results: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician-(47,025 forms) and patient-(54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade >= 2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung).Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers.Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short-and long-term quality-of-life. Not all patients are equally sensitive to radiation {"}damage{"} but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available.In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries.In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity. (C) 2019 The Authors. Published by Elsevier B.V.",

keywords = "Late radiotherapy side effects, Biomarkers, Prediction models, Breast cancer, Prostate cancer, Lung cancer, QUALITY-OF-LIFE, GENOME-WIDE ASSOCIATION, DATA METAANALYSIS SHOWS, REPORTED OUTCOMES, RADIATION-THERAPY, EUROPEAN-ORGANIZATION, NO ASSOCIATION, LATE TOXICITY, RISK, POLYMORPHISMS",

author = "Petra Seibold and Adam Webb and Aguado-Barrera, {Miguel E.} and David Azria and Celine Bourgier and Muriel Brengues and Erik Briers and Renee Bultijnck and Patricia Calvo-Crespo and Ana Carballo and Ananya Choudhury and Alessandro Cicchetti and Johannes Classen and Elena Delmastro and Dunning, {Alison M.} and Elliott, {Rebecca M.} and Laura Fachal and Marie-Pierre Farcy-Jacquet and Pietro Gabriele and Elisabetta Garibaldi and Antonio Gomez-Caamano and Sara Gutierrez-Enriquez and Higginson, {Daniel S.} and Kerstie Johnson and Ramon Lobato-Busto and Meritxell Molla and Anusha Mueller and Debbie Payne and Paula Peleteiro and Giselle Post and Tiziana Rancati and Tim Rattay and Victoria Reyes and Rosenstein, {Barry S.} and {De Ruysscher}, Dirk and {De Santis}, {Maria Carmen} and Joerg Schaefer and Thomas Schnabel and Elena Sperk and Symonds, {R. Paul} and Hilary Stobart and Begona Taboada-Valladares and Talbot, {Christopher J.} and Riccardo Valdagni and Ana Vega and Liv Veldeman and Tim Ward and Christian Weissenberger and Ben Vanneste and Ahmed Osman and {REQUITE consortium}",

note = "Funding Information: As several toxicities such as breast fibrosis may emerge many years after completion of radiotherapy, follow-up beyond two years is desirable. A longer follow-up would also allow assessment of fluctuations in symptoms over time. Funding for an extension of the follow-up to five years in some centres was secured through an ERA PERMED grant. Funding Information: REQUITE received funding from the European Union's Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 601826. We sincerely thank all patients that participated in the REQUITE study and all REQUITE staff involved at the following sites: Belgium: Ghent University Hospital; KU Leuven. France: ICM Montpellier, CHU N{\^i}mes (Department of Radiation Oncology, CHU N{\^i}mes, N{\^i}mes, France). Germany: Praxis f{\"u}r Strahlentherapie an der Stadtklinik Baden-Baden; Klinikum Darmstadt GmbH; Zentrum f{\"u}r Strahlentherapie Freiburg; St{\"a}dtisches Klinikum Karlsruhe; St. Vincentius-Kliniken gAG Karlsruhe; Klinikum der Stadt Ludwigshafen GmbH; Universit{\"a}tsklinikum Mannheim: Anke Keller and Christiane Zimmermann; Strahlentherapie Speyer. The researchers at DKFZ also thank Dr Sabine Behrens and Kerstin Pieper. Italy: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Candiolo Cancer Institute – FPO, IRCCS. The Netherlands: Sylvie Canisius at Maastro Clinics, Maastricht. Spain: Santiago: Complexo Hospitalario Universitario de Santiago. Ana Vega is supported by Spanish Instituto de Salud Carlos III (ISCIII) funding, an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (INT15/00070, INT16/00154, INT17/00133; PI16/00046; PI13/02030; PI10/00164), and through the Autonomous Government of Galicia (Consolidation and structuring program: IN607B); Barcelona: The authors acknowledge the Cellex Foundation for providing research facilities and equipment. S. Guti{\'e}rrez-Enr{\'i}quez is supported by the Miguel Servet Program from ISCIII (CPII16/00034). UK: University Hospitals of Leicester NHS Trust, Dr Tim Rattay was funded by a National Institute of Health Research (NIHR) Doctoral Research Fellowship (DRF-2014-07-079); Manchester: Jacki Routledge at Christie NHS Foundation Trust, Manchester. Catharine West, Ananya Choudhury and Rebecca Elliott are supported by NIHR Manchester Biomedical Research Centre and Catharine West is supported by Cancer Research UK (C1094/A18504, C147/A25254); University Hospitals Birmingham NHS Foundation Trust; Derby Hospitals NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Salford Royal NHS Trust. USA: Mount Sinai Hospital, New York; Memorial Sloan Kettering Cancer Center, New York. D. Azria is involved in the creation of the start-up NovaGray in 2015. D. De Ruysscher: none related to the current manuscript. Outside the current manuscript: advisory board of Astra Zeneca, Bristol-Myers-Squibb, Roche/Genentech, Merck/Pfizer, Celgene, Noxxon, Mologen and has received investigator initiated grants from Bristol-Myers-Squibb, Boehringer Ingelheim and Astra-Zeneca. E. Sperk: none related to the current manuscript. Outside the current manuscript: General speakers bureau Zeiss Meditec, travel support Zeiss Meditec. The other authors have no conflict of interest to declare. Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2019",

month = sep,

doi = "10.1016/j.radonc.2019.04.034",

language = "English",

volume = "138",

pages = "59--67",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

}

Seibold, P, Webb, A, Aguado-Barrera, ME, Azria, D, Bourgier, C, Brengues, M, Briers, E, Bultijnck, R, Calvo-Crespo, P, Carballo, A, Choudhury, A, Cicchetti, A, Classen, J, Delmastro, E, Dunning, AM, Elliott, RM, Fachal, L, Farcy-Jacquet, M-P, Gabriele, P, Garibaldi, E, Gomez-Caamano, A, Gutierrez-Enriquez, S, Higginson, DS, Johnson, K, Lobato-Busto, R, Molla, M, Mueller, A, Payne, D, Peleteiro, P, Post, G, Rancati, T, Rattay, T, Reyes, V, Rosenstein, BS, De Ruysscher, D, De Santis, MC, Schaefer, J, Schnabel, T, Sperk, E, Symonds, RP, Stobart, H, Taboada-Valladares, B, Talbot, CJ, Valdagni, R, Vega, A, Veldeman, L, Ward, T, Weissenberger, C, Vanneste, B, Osman, A & REQUITE consortium 2019, 'REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer', Radiotherapy and Oncology, vol. 138, pp. 59-67. https://doi.org/10.1016/j.radonc.2019.04.034

TY - JOUR

T1 - REQUITE

T2 - A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

AU - Seibold, Petra

AU - Webb, Adam

AU - Aguado-Barrera, Miguel E.

AU - Azria, David

AU - Bourgier, Celine

AU - Brengues, Muriel

AU - Briers, Erik

AU - Bultijnck, Renee

AU - Calvo-Crespo, Patricia

AU - Carballo, Ana

AU - Choudhury, Ananya

AU - Cicchetti, Alessandro

AU - Classen, Johannes

AU - Delmastro, Elena

AU - Dunning, Alison M.

AU - Elliott, Rebecca M.

AU - Fachal, Laura

AU - Farcy-Jacquet, Marie-Pierre

AU - Gabriele, Pietro

AU - Garibaldi, Elisabetta

AU - Gomez-Caamano, Antonio

AU - Gutierrez-Enriquez, Sara

AU - Higginson, Daniel S.

AU - Johnson, Kerstie

AU - Lobato-Busto, Ramon

AU - Molla, Meritxell

AU - Mueller, Anusha

AU - Payne, Debbie

AU - Peleteiro, Paula

AU - Post, Giselle

AU - Rancati, Tiziana

AU - Rattay, Tim

AU - Reyes, Victoria

AU - Rosenstein, Barry S.

AU - De Ruysscher, Dirk

AU - De Santis, Maria Carmen

AU - Schaefer, Joerg

AU - Schnabel, Thomas

AU - Sperk, Elena

AU - Symonds, R. Paul

AU - Stobart, Hilary

AU - Taboada-Valladares, Begona

AU - Talbot, Christopher J.

AU - Valdagni, Riccardo

AU - Vega, Ana

AU - Veldeman, Liv

AU - Ward, Tim

AU - Weissenberger, Christian

AU - Vanneste, Ben

AU - Osman, Ahmed

AU - REQUITE consortium

N1 - Funding Information: As several toxicities such as breast fibrosis may emerge many years after completion of radiotherapy, follow-up beyond two years is desirable. A longer follow-up would also allow assessment of fluctuations in symptoms over time. Funding for an extension of the follow-up to five years in some centres was secured through an ERA PERMED grant. Funding Information: REQUITE received funding from the European Union's Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 601826. We sincerely thank all patients that participated in the REQUITE study and all REQUITE staff involved at the following sites: Belgium: Ghent University Hospital; KU Leuven. France: ICM Montpellier, CHU Nîmes (Department of Radiation Oncology, CHU Nîmes, Nîmes, France). Germany: Praxis für Strahlentherapie an der Stadtklinik Baden-Baden; Klinikum Darmstadt GmbH; Zentrum für Strahlentherapie Freiburg; Städtisches Klinikum Karlsruhe; St. Vincentius-Kliniken gAG Karlsruhe; Klinikum der Stadt Ludwigshafen GmbH; Universitätsklinikum Mannheim: Anke Keller and Christiane Zimmermann; Strahlentherapie Speyer. The researchers at DKFZ also thank Dr Sabine Behrens and Kerstin Pieper. Italy: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Candiolo Cancer Institute – FPO, IRCCS. The Netherlands: Sylvie Canisius at Maastro Clinics, Maastricht. Spain: Santiago: Complexo Hospitalario Universitario de Santiago. Ana Vega is supported by Spanish Instituto de Salud Carlos III (ISCIII) funding, an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (INT15/00070, INT16/00154, INT17/00133; PI16/00046; PI13/02030; PI10/00164), and through the Autonomous Government of Galicia (Consolidation and structuring program: IN607B); Barcelona: The authors acknowledge the Cellex Foundation for providing research facilities and equipment. S. Gutiérrez-Enríquez is supported by the Miguel Servet Program from ISCIII (CPII16/00034). UK: University Hospitals of Leicester NHS Trust, Dr Tim Rattay was funded by a National Institute of Health Research (NIHR) Doctoral Research Fellowship (DRF-2014-07-079); Manchester: Jacki Routledge at Christie NHS Foundation Trust, Manchester. Catharine West, Ananya Choudhury and Rebecca Elliott are supported by NIHR Manchester Biomedical Research Centre and Catharine West is supported by Cancer Research UK (C1094/A18504, C147/A25254); University Hospitals Birmingham NHS Foundation Trust; Derby Hospitals NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Salford Royal NHS Trust. USA: Mount Sinai Hospital, New York; Memorial Sloan Kettering Cancer Center, New York. D. Azria is involved in the creation of the start-up NovaGray in 2015. D. De Ruysscher: none related to the current manuscript. Outside the current manuscript: advisory board of Astra Zeneca, Bristol-Myers-Squibb, Roche/Genentech, Merck/Pfizer, Celgene, Noxxon, Mologen and has received investigator initiated grants from Bristol-Myers-Squibb, Boehringer Ingelheim and Astra-Zeneca. E. Sperk: none related to the current manuscript. Outside the current manuscript: General speakers bureau Zeiss Meditec, travel support Zeiss Meditec. The other authors have no conflict of interest to declare. Publisher Copyright: © 2019 The Authors

PY - 2019/9

Y1 - 2019/9

N2 - Purpose: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data.Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated.Results: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician-(47,025 forms) and patient-(54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade >= 2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung).Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers.Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short-and long-term quality-of-life. Not all patients are equally sensitive to radiation "damage" but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available.In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries.In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity. (C) 2019 The Authors. Published by Elsevier B.V.

AB - Purpose: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data.Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated.Results: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician-(47,025 forms) and patient-(54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade >= 2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung).Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers.Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short-and long-term quality-of-life. Not all patients are equally sensitive to radiation "damage" but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available.In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries.In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity. (C) 2019 The Authors. Published by Elsevier B.V.

KW - Late radiotherapy side effects

KW - Biomarkers

KW - Prediction models

KW - Breast cancer

KW - Prostate cancer

KW - Lung cancer

KW - QUALITY-OF-LIFE

KW - GENOME-WIDE ASSOCIATION

KW - DATA METAANALYSIS SHOWS

KW - REPORTED OUTCOMES

KW - RADIATION-THERAPY

KW - EUROPEAN-ORGANIZATION

KW - NO ASSOCIATION

KW - LATE TOXICITY

KW - RISK

KW - POLYMORPHISMS

U2 - 10.1016/j.radonc.2019.04.034

DO - 10.1016/j.radonc.2019.04.034

M3 - Article

SN - 0167-8140

VL - 138

SP - 59

EP - 67

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

ER -

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this